Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03284931 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT03284931 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 45 participants.
The verdict
NCT03284931, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study will assess the pharmacodynamic effects of SAGE-217 in approximately 42 healthy adult subjects using an insomnia model.
Interventions
- DRUG Placebo
- DRUG SAGE-217 high dose
- DRUG SAGE-217 low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-09-14 |
| Est. Completion | 2017-12-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03284931
The ClinicalTrials.gov registry entry for NCT03284931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03284931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03284931 about?
NCT03284931 is a clinical study titled "A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model". This study will assess the pharmacodynamic effects of SAGE-217 in approximately 42 healthy adult subjects using an insomnia model.
What is the current status of trial NCT03284931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2017-09-14. Estimated completion is 2017-12-18.
What interventions are being tested in trial NCT03284931?
The interventions under investigation include: Placebo (DRUG), SAGE-217 high dose (DRUG), SAGE-217 low dose (DRUG).
Who is sponsoring clinical trial NCT03284931?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.